PALO ALTO, Calif.–(BUSINESS WIRE)–Medable Inc, the main cloud platform for patient-centered drug growth, right now introduced the hiring of Andrea Valente as chief working officer. Valente is a veteran life sciences know-how chief who brings deep expertise delivering scientific trial applied sciences to sufferers at international scale. She has managed operations, product and repair supply for Oracle, IBM, ERT, Siemens and Part Ahead.
As analysis and affected person care transfer from the managed setting of the clinic to the house, give attention to operational excellence is paramount. Valente is a confirmed skilled in operationalizing affected person applied sciences in scientific analysis. She performed an early position driving adoption and scale of digital Scientific Consequence Assessments (eCOAs), one of many first know-how classes to work together immediately with sufferers outdoors of scientific settings. She most not too long ago led growth and launch of Oracle’s public well being platform to deal with COVID-19 pandemic response and vaccine trials within the U.S., UK and a number of other creating nations.
“Andrea shouldn’t be solely an completed chief however she has industry-leading expertise delivering applied sciences on to sufferers, everywhere in the world. That is very totally different than delivering options into the confines of a clinic,” stated Dr. Michelle Longmire, CEO and co-founder of Medable. “Andrea is aware of what it takes to attain operational excellence at international scale. She shall be a useful addition to our management staff as we proceed to execute on our mission to construct a extremely impactful life sciences know-how firm.”
Medable skilled document development in 2020 because the COVID-19 pandemic drove demand for distant scientific trial applied sciences. By minimizing the necessity for in-person website visits, Medable clients have achieved unprecedented outcomes – together with 3X sooner enrollment and over 90 p.c retention charges. Medable launched 5 new merchandise and onboarded greater than 50 new purchasers throughout the 12 months, rising revenues by greater than 400 p.c – and fueling $118 million in new funding to speed up digital and decentralized scientific trial adoption.
“I’m thrilled to hitch a management staff that appears at this area with contemporary eyes, whereas studying from the previous – and never essentially repeating it,” stated Valente. “Medable is actually reworking scientific analysis with a relentless give attention to the affected person expertise and end-to-end course of effectivity. We’re scaling globally with consulting and implementation companies which might be grounded in science, scientific analysis and knowledge evaluation – throughout a number of therapeutic areas.”
Medable executives are participating in several events at this week’s J.P. Morgan Healthcare Convention, sharing insights, recommendation and classes discovered from the entrance strains of decentralized trial adoption. Please click on here for extra details about Medable’s presence at JPM 2021, or to schedule a gathering with Medable’s executives.
Medable is on a mission to get efficient therapies to sufferers sooner by reworking scientific drug growth with disruptive applied sciences. The corporate’s digital platform streamlines design, recruitment, retention and knowledge high quality for decentralized trials, changing siloed methods with built-in digital instruments, knowledge and interfaces to speed up trial execution. Medable connects sufferers, websites and scientific trial groups to enhance affected person entry, expertise, and outcomes. Medable is a privately held, venture-backed firm headquartered in Palo Alto, California.